Witnessing the stock’s movement on the chart, on Wednesday, Myriad Genetics, Inc. (NASDAQ: MYGN) had a quiet start as it plunged -0.45% to $28.47, before settling in for the price of $28.60 at the close. Taking a more long-term approach, MYGN posted a 52-week range of $13.82-$29.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 4.63% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 135.75%. This publicly-traded company’s shares outstanding now amounts to $89.90 million, simultaneously with a float of $87.20 million. The organization now has a market capitalization sitting at $2.59 billion. At the time of writing, stock’s 50-day Moving Average stood at $27.36, while the 200-day Moving Average is $23.02.
Myriad Genetics, Inc. (MYGN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Diagnostics & Research industry. Myriad Genetics, Inc.’s current insider ownership accounts for 3.99%, in contrast to 101.98% institutional ownership. Preceding that transaction, on Sep 11 ’24, Company’s President and CEO sold 15,000 for 26.72, making the whole transaction’s value amount to 400,800. This particular insider is now the holder of 977,378 in total.
Myriad Genetics, Inc. (MYGN) Earnings and Revenue Records
Myriad Genetics, Inc.’s EPS increase for this current 12-month fiscal period is 135.75% and is forecasted to reach 0.28 in the upcoming year.
Myriad Genetics, Inc. (NASDAQ: MYGN) Trading Performance Indicators
Let’s observe the current performance indicators for Myriad Genetics, Inc. (MYGN). It’s Quick Ratio in the last reported quarter now stands at 1.78. The Stock has managed to achieve an average true range (ATR) of 1.07. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.22.
In the same vein, MYGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.81, a figure that is expected to reach 0.02 in the next quarter, and analysts are predicting that it will be 0.28 at the market close of one year from today.
Technical Analysis of Myriad Genetics, Inc. (MYGN)
Going through the that latest performance of [Myriad Genetics, Inc., MYGN]. Its last 5-days volume of 0.69 million was inferior to the volume of 0.72 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 88.63% While, its Average True Range was 1.07.
Raw Stochastic average of Myriad Genetics, Inc. (MYGN) in the period of the previous 100 days is set at 92.72%, which indicates a major rise in contrast to 81.80% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 58.87% that was higher than 48.37% volatility it exhibited in the past 100-days period.
